Adams Tackles Branding By Linking Mucinex To Mucus, Not Indications
This article was originally published in The Tan Sheet
Executive Summary
Adams Respiratory Therapeutics competes head on with larger firms in the over-the-counter market, but on its own terms using untraditional approaches to building brand recognition, Adams President and CEO Michael Valentino says
You may also be interested in...
Adams Delays New Humibid Launches, Mucinex Drives Record Overall Sales
In the midst of strong growth from flagship brand Mucinex, Adams is delaying the launch of new Humibid products to train pharmacists in behind-the-counter sale of the OTC drug
Adams Labs Mucinex Marketing Strategy Targeting Healthcare Professionals
Adams Laboratories plans to launch Mucinex "long-acting" guaifenesin tablets with a behind-the-counter sales strategy
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”